# EDGAR Filing Document

**Accession Number:** 0002077508
**File Stem:** 0001193125-25-193495
**Filing Date:** 2025-9
**Character Count:** 52728
**Document Hash:** fa5ee9eca6b64bd834f7db3cb218bf8c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-193495.hdr.sgml**: 20250902

**ACCESSION NUMBER**: 0001193125-25-193495

**CONFORMED SUBMISSION TYPE**: POSASR

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250902

**DATE AS OF CHANGE**: 20250902

**EFFECTIVENESS DATE**: 20250902

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Royalty Pharma plc
- **CENTRAL INDEX KEY:** 0001802768
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POSASR
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-279905
- **FILM NUMBER:** 251283229

**BUSINESS ADDRESS:**
- **STREET 1:** 110 EAST 59TH STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** (212) 883-0200

**MAIL ADDRESS:**
- **STREET 1:** 110 EAST 59TH STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Royalty Pharma Manager, LLC
- **CENTRAL INDEX KEY:** 0002077508

**ORGANIZATION NAME:**
- **EIN:** 611450238
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POSASR
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-279905-02
- **FILM NUMBER:** 251283230

**BUSINESS ADDRESS:**
- **STREET 1:** 110 E. 59TH STREET
- **STREET 2:** SUITE 3300
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-883-0200

**MAIL ADDRESS:**
- **STREET 1:** 110 E. 59TH STREET
- **STREET 2:** SUITE 3300
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Royalty Pharma Holdings Ltd.
- **CENTRAL INDEX KEY:** 0001868134

**ORGANIZATION NAME:**
- **EIN:** 981526515
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POSASR
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-279905-01
- **FILM NUMBER:** 251283231

**BUSINESS ADDRESS:**
- **STREET 1:** 110 EAST 59TH STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 212-883-0200

**MAIL ADDRESS:**
- **STREET 1:** 110 EAST 59TH STREET
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022

**As filed with the Securities and Exchange Commission on September 2, 2025** 

**Registration No. 333- 279905** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**POST-EFFECTIVE AMENDMENT NO. 1** 

**TO** 

**FORM S-3** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

**Royalty Pharma plc\*** 

**(Exact Name of Registrant as Specified in Its Charter)** 

---

| | |
|:---|:---|
| **England and Wales** | **98-1535773** |
| **(State or Other Jurisdiction of**<br> **Incorporation or Organization)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**110 East 59<sup>th</sup> Street** 

**New York, New York 10022** 

**(212) 883-0200** 

**(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)** 

**Pablo Legorreta** 

**Chief Executive Officer** 

**110 East 59<sup>th</sup> Street** 

**New York, New York 10022** 

**(212) 883-0200** 

**(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)** 

***Copy to:***

**Richard D. Truesdell, Jr., Esq.** 

**Davis Polk & Wardwell LLP** 

**450 Lexington Avenue** 

**New York, New York 10017** 

**(212) 450-4000** 

**Approximate date of commencement of proposed sale to the public**: From time to time after this Registration Statement becomes effective.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**\*** **Certain subsidiaries of Royalty Pharma plc are also registrants and are identified on the following page.** 

------

**ADDITIONAL REGISTRANTS** 

---

| | | |
|:---|:---|:---|
| **Exact Name of Registrant as Specified in Its Charter** | **State or Other<br>Jurisdiction of<br>Incorporation or<br>Organization** | **I.R.S. Employer<br>Identification<br>Number** |
|  Royalty Pharma Holdings Ltd \* | England and Wales | 98-1526515 |
|  Royalty Pharma Manager, LLC \* | Delaware | 61-1450238 |

---

\* The address, including zip code, and telephone number, including area code, of the Registrant's principal executive offices is 110 East 59<sup>th</sup> Street, New York, New York 10022, Tel. (212) 883-0200.

------

**EXPLANATORY NOTE** 

This Amendment No. 1 to the Registration Statement on Form S-3 (Registration No. 333-279905) (the "Registration Statement") of Royalty Pharma plc (the "Company") is being filed to add Royalty Pharma Manager, LLC, an indirect subsidiary of the Company, as a co-registrant. No changes or additions are being made to the prospectus that forms a part of the Registration Statement. Accordingly, such prospectus is omitted from this filing.

------

**PART II** 

**INFORMATION NOT REQUIRED IN PROSPECTUS** 

**Item 14.** **Other Expenses of Issuance and Distribution** <br>

The following table sets forth the costs and expenses payable by the Registrants in connection with the sale of the securities being registered hereby.

---

| | |
|:---|:---|
|  | **Amount to be<br>Paid** |
|  SEC registration fee | $<sup>(1)</sup> |
|  Printing and distributing | <sup>(2)</sup> |
|  Legal fees and expenses (including blue sky fees) | <sup>(2)</sup> |
|  Trustee fees and expenses | <sup>(2)</sup> |
|  Rating agency fees | <sup>(2)</sup> |
|  Accounting fees and expenses | <sup>(2)</sup> |
|  Miscellaneous | <sup>(2)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TOTAL | $— |

---

<sup>(1)</sup> This registration statement relates to the registration of securities having an indeterminate aggregate offering price and number or amount. Payment of the registration fee has been deferred and will be calculated and paid in accordance with Rule 456(b) and Rule 457(r) under the Securities Act. 

<sup>(2)</sup> The estimated total amount of fees and expenses to be incurred in connection with any offering of securities pursuant to this registration statement will be determined from time to time and reflected in the applicable prospectus supplement. 

**Item 15.** **Indemnification of Directors and Officers** <br>

We have entered into indemnification agreements with our directors and executive officers to indemnify them to the maximum extent allowed under applicable law. These agreements indemnify these individuals against certain costs, charges, losses, liabilities, damages and expenses incurred by such director or officer in the execution or discharge of his or her duties or the exercise of his or her powers or otherwise in relation to or in connection with his or her duties, powers or office. These agreements do not indemnify our directors against any liability attaching to such individuals in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he or she is a director, which would be rendered void under the Companies Act.

The Company also maintains directors and officers insurance to insure such persons against certain liabilities.

Royalty Pharma Manager, LLC is a limited liability company formed in the State of Delaware. Section 18-108 of the Delaware Limited Liability Company Act provides that a limited liability company may, and has the power to, indemnify and hold harmless any member or manager or other person from and against any and all claims and demands whatsoever. The Second Amended and Restated Limited Liability Company Agreement of the Royalty Pharma Manager, LLC provides that it will indemnify and hold harmless any person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding, by reason of the fact that such person is or was a member, manager or officer of Royalty Pharma Manager, LLC or is or was serving at the request of Royalty Pharma Manager, LLC as a member, manager or director of another corporation, limited liability company, partnership, joint venture, trust or other enterprise.

In the underwriting agreement, the underwriters will agree to indemnify, under certain conditions, the Company, members of the Company's board of directors, and persons who control the Company within the meaning of the Securities Act against certain liabilities.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us under the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

The indemnification rights set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, provision of our Articles, agreement, vote of shareholders or disinterested directors or otherwise.

------

**Item 16.** **Exhibits** <br>

The following exhibits are filed as part of this Registration Statement:

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Document** |
| &nbsp;&nbsp;&nbsp;&nbsp;1.1 | Form of Underwriting Agreement relating to Class A ordinary shares, preference shares, debt securities, warrants, purchase contracts and units of Royalty Pharma plc \*\* |
| &nbsp;&nbsp;&nbsp;&nbsp;3.1 | [Amended and Restated Articles of Association of Royalty Pharma plc](http://www.sec.gov/Archives/edgar/data/1802768/000095010325006186/dp228958_ex0301.htm) <sup>(1)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;3.2 | [Amended and Restated Articles of Association of Royalty Pharma Holdings Ltd](http://www.sec.gov/Archives/edgar/data/1802768/000095010325006186/dp228958_ex0302.htm) <sup>(2)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee](http://www.sec.gov/Archives/edgar/data/1802768/000095010320017365/dp135934_ex0401.htm) <sup>(3)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Fourth Supplemental Indenture, dated as of June 9, 2025, among Royalty Pharma plc, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and Wilmington Trust, National Association, as Trustee](http://www.sec.gov/Archives/edgar/data/1802768/000180276825000095/rprx-20250630ex106.htm) <sup>(4)</sup> |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Form of Subordinated Indenture between Royalty Pharma plc, the guarantors party thereto and Wilmington Trust, National Association, as Trustee](http://www.sec.gov/Archives/edgar/data/1802768/000119312524152416/d811721dex44.htm) (previously filed as Exhibit 4.4 to the Registration Statement) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.4 | Form of Senior Note \*\* |
| &nbsp;&nbsp;&nbsp;&nbsp;4.5 | Form of Subordinated Note \*\* |
| &nbsp;&nbsp;&nbsp;&nbsp;4.6 | Form of Warrant Agreement \*\* |
| &nbsp;&nbsp;&nbsp;&nbsp;4.7 | Form of Purchase Contract Agreement \*\* |
| &nbsp;&nbsp;&nbsp;&nbsp;4.8 | Form of Unit Agreement \*\* |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1 | [Opinion of Davis Polk & Wardwell LLP](d949871dex51.htm) \* |
| &nbsp;&nbsp;&nbsp;&nbsp;5.2 | [Opinion of Davis Polk & Wardwell London LLP](http://www.sec.gov/Archives/edgar/data/1802768/000119312524152416/d811721dex52.htm) (previously filed as Exhibit 5.2 to the Registration Statement) |
| 23.1 | [Consent of Ernst & Young LLP \*](d949871dex231.htm) |
| 23.2 | [Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1)](d949871dex51.htm) |
| 23.3 | [Consent of Davis Polk & Wardwell London LLP (included in Exhibit 5.2)](http://www.sec.gov/Archives/edgar/data/1802768/000119312524152416/d811721dex52.htm) |
| 24.1 | [Powers of Attorney for Royalty Pharma plc (previously included on the signature pages of the Registration Statement and included on the signature pages of this Amendment No. 1 to the Registration Statement)](d949871dposasr.htm#sig1) |
| 24.2 | [Powers of Attorney for Royalty Pharma Holdings Ltd (included on the signature pages of this Amendment No. 1 to the Registration Statement)](d949871dposasr.htm#sig2) |
| 24.3 | [Powers of Attorney for Royalty Pharma Manager, LLC (included on the signature pages of this Amendment No. 1 to the Registration Statement)](d949871dposasr.htm#sig3) |
| 25.1 | [Statement of Eligibility on Form T-1 of Wilmington Trust, National Association for Senior Indenture of Royalty Pharma plc](http://www.sec.gov/Archives/edgar/data/1802768/000119312524152416/d811721dex251.htm) (previously filed as Exhibit 25.1 to the Registration Statement) |
| 25.2 | [Statement of Eligibility on Form T-1 of Wilmington Trust, National Association for Subordinated Indenture of Royalty Pharma plc](http://www.sec.gov/Archives/edgar/data/1802768/000119312524152416/d811721dex252.htm) (previously filed as Exhibit 25.2 to the Registration Statement) |
| 107 | [Filing Fee Table \*](d949871dexfilingfees.htm) |

---

\* Filed herewith.

\*\* To be filed by amendment or as an exhibit to a document to be incorporated by reference herein in connection with an offering of the offered securities.

<sup>(1)</sup> Incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-39329), filed with the SEC on May 19, 2025.

<sup>(2)</sup> Incorporated herein by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-39329), filed with the SEC on May 19, 2025.

<sup>(3)</sup> Incorporated herein by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-39329), filed with the SEC on September 2, 2020.

<sup>(4)</sup> Incorporated herein by reference to Exhibit 10.6 to the Registrant's Current Report on Form 10-Q (File No. 001-39329), filed with the SEC on August 6, 2025.

------

**Item 17. Undertakings** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The undersigned Registrants hereby undertake:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made of securities registered hereby, a post-effective amendment to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" or "Calculation of Registration Fee" table, as applicable, in the effective registration statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; 

*provided*, *however*, that paragraphs (i), (ii) and (iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) That, for the purpose of determining liability under the Securities Act to any purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities:

The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The undersigned Registrants hereby undertake that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrants pursuant to the foregoing provisions, or otherwise, the registrants have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrants will, unless in the opinion of their counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant below certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on September 2, 2025.

---

| | | |
|:---|:---|:---|
| ROYALTY PHARMA PLC | ROYALTY PHARMA PLC | ROYALTY PHARMA PLC |
| By: | /s/ Pablo Legorreta | /s/ Pablo Legorreta |
|  | Name: | Pablo Legorreta |
|  | Title: | Chief Executive Officer |

---

Each person whose signature appears below constitutes and appoints Terrance Coyne and George Lloyd, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power to act separately and full power of substitution and resubstitution, for him and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or his, her or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| \*<br> Pablo Legorreta | Chairman of the Board, Director &<br> Chief Executive Officer (Principal Executive Officer and Royalty Pharma plc's authorized representative in the United States) | September 2, 2025 |
| /s/ Terrance Coyne<br> Terrance Coyne | Executive Vice President & Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | September 2, 2025 |
| \*<br> Bonnie Bassler | Director | September 2, 2025 |
| /s/ Vlad Coric<br> Vlad Coric | Director | September 2, 2025 |
| \*<br> Errol De Souza | Director | September 2, 2025 |
| \*<br> Catherine Engelbert | Director | September 2, 2025 |
| /s/ Carole Ho<br> Carole Ho | Director | September 2, 2025 |
| \*<br> David Hodgson | Director | September 2, 2025 |

---

------

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| \*<br> Ted Love | Director | September 2, 2025 |
| \*<br> Gregory Norden | Director | September 2, 2025 |
| /s/ Elizabeth Weatherman<br> Elizabeth Weatherman | Director | September 2, 2025 |

---

---

| | | |
|:---|:---|:---|
| By: | /s/ Terrance Coyne | /s/ Terrance Coyne |
|  | Name: | Terrance Coyne |
|  | Title: | Attorney-in-fact |

---

------

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant below certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on September 2, 2025.

---

| | | |
|:---|:---|:---|
| ROYALTY PHARMA HOLDINGS LTD | ROYALTY PHARMA HOLDINGS LTD | ROYALTY PHARMA HOLDINGS LTD |
| By: | /s/ Pablo Legorreta | /s/ Pablo Legorreta |
|  | Name: | Pablo Legorreta |
|  | Title: | Director |

---

Each person whose signature appears below constitutes and appoints Terrance Coyne and George Lloyd, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power to act separately and full power of substitution and resubstitution, for him and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or his, her or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Pablo Legorreta<br> Pablo Legorreta | Director (Principal Executive Officer and Royalty Pharma Holdings Ltd's authorized representative in the United States) | September 2, 2025 |
| /s/ Terrance Coyne<br> Terrance Coyne | Director (Principal Financial Officer and Principal Accounting Officer) | September 2, 2025 |
| /s/ George Lloyd<br> George Lloyd | Director | September 2, 2025 |

---

------

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant below certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on September 2, 2025.

---

| | | |
|:---|:---|:---|
| ROYALTY PHARMA MANAGER, LLC | ROYALTY PHARMA MANAGER, LLC | ROYALTY PHARMA MANAGER, LLC |
| By: | /s/ Pablo Legorreta | /s/ Pablo Legorreta |
|  | Name: | Pablo Legorreta |
|  | Title: | Chief Executive Officer |

---

Each person whose signature appears below constitutes and appoints Terrance Coyne and George Lloyd, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power to act separately and full power of substitution and resubstitution, for him and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or his, her or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Pablo Legorreta<br> Pablo Legorreta | Chief Executive Officer & Manager<br> (Principal Executive Officer) | September 2, 2025 |
| /s/ Terrance Coyne<br> Terrance Coyne | Executive Vice President & Chief Financial Officer & Manager (Principal Financial Officer and Principal Accounting Officer) | September 2, 2025 |
| /s/ George Lloyd<br> George Lloyd | Executive Vice President,<br> Investments & Chief Legal Officer & Manager | September 2, 2025 |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g949871g63o40.jpg) | Davis Polk & Wardwell LLP<br> 450 Lexington Avenue <br>New York, NY 10017<br> davispolk.com<br> +1 212 450 4000 |

---

September 2, 2025

Royalty Pharma plc

110 East 59th Street

New York, NY 10022

Ladies and Gentlemen:

Royalty Pharma plc, an English public limited company organized under the laws of England and Wales (the "**Company**"), is filing with the Securities and Exchange Commission a Registration Statement on Form S-3 (as amended, the "**Registration Statement**") for the purpose of registering under the Securities Act of 1933, as amended (the "**Securities Act**"), (i) (a) Class A Ordinary Shares, par value $0.001 per share (the "**Ordinary Shares**") of the Company; (b) preference shares (the "**Preference Shares**") of the Company; (c) the Company's senior debt securities and subordinated debt securities (collectively, the "**Debt Securities**"), which may be fully and unconditionally guaranteed by one or more of the subsidiaries of the Company listed on Schedule 1 hereto (the "**Guarantors**") and which may be issued pursuant to a senior debt indenture, among the Company, the Guarantors and Wilmington Trust, National Association, as trustee (the "**Senior Debt Trustee**") (the "**Senior Debt Indenture**") and a subordinated debt indenture among the Company, the Guarantors and Wilmington Trust, National Association, as trustee (the "**Subordinated Debt Trustee**" and, together with the Senior Debt Trustee, the "**Trustees**") (the "**Subordinated Debt Indenture**," and together with the Senior Debt Indenture, the "**Indentures**"); (d) warrants of the Company (the "**Warrants**"), which may be issued under one or more warrant agreements (each, a "**Warrant Agreement**") to be entered into between the Company and the warrant agent to be named therein (the "**Warrant Agent**"); (e) purchase contracts (the "**Purchase Contracts**") which may be issued under one or more purchase contract agreements (each, a **"Purchase Contract Agreement**") to be entered into between the Company and the purchase contract agent to be named therein (the "**Purchase Contract Agent**"); (f) units (the "**Units**") to be issued under one or more unit agreements to be entered into among the Company, a bank or trust company, as unit agent (the "**Unit Agent**"), and the holders from time to time of the Units (each such unit agreement, a "**Unit Agreement**") and (g) guarantees (the "**Guarantees**") of the Debt Securities by the Guarantors, to be issued under the Indentures.

We, as your counsel, have examined originals or copies of such documents, corporate records, certificates of public officials and other instruments as we have deemed necessary or advisable for the purpose of rendering this opinion.

In rendering the opinions expressed herein, we have, without independent inquiry or investigation, assumed that (i) all documents submitted to us as originals are authentic and complete, (ii) all documents submitted to us as copies conform to authentic, complete originals, (iii) all documents filed as exhibits to the Registration Statement that have not been executed will conform to the forms thereof, (iv) all signatures on all documents that we reviewed are genuine, (v) all natural persons executing documents had and have the legal capacity to do so, (vi) all statements in certificates of public officials and officers of the Company and the Guarantors that we reviewed were and are accurate and (vii) all representations made by the Company and the Guarantors as to matters of fact in the documents that we reviewed were and are accurate.

------

---

| | |
|:---|:---|
| ![LOGO](g949871g63o40.jpg) | Royalty Pharma plc |

---

Based upon the foregoing, and subject to the additional assumptions and qualifications set forth below, we advise you that, in our opinion:

1. Assuming the Indentures and any supplemental indenture to be entered into in connection with the issuance of
any Debt Securities have been duly authorized, executed and delivered by the Trustees and the Company and, if applicable, the Guarantors; the specific terms of a particular series of Debt Securities and the related Guarantees have been duly
authorized and established in accordance with the Indentures; and such Debt Securities and the related Guarantees have been duly authorized, executed, authenticated, issued and delivered in accordance with the Indenture and the applicable
underwriting or other agreement against payment therefor, such Debt Securities will constitute valid and binding obligations of the Company and each of the related Guarantees will constitute valid and binding obligations of each respective
Guarantor, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors' rights generally, concepts of reasonableness and equitable principles of general applicability, and may
be subject to possible judicial or regulatory actions giving effect to governmental actions or foreign laws affecting creditors' rights, provided that we express no opinion as to (x) the enforceability of any waiver of rights under
any usury or stay law, (y) (i) the effect of fraudulent conveyance, fraudulent transfer or similar provision of applicable law on the conclusions expressed above or (ii) any provision of the Indenture that purports to avoid the effect of
fraudulent conveyance, fraudulent transfer or similar provision of applicable law by limiting the amount of any Guarantor's obligation, or (z) the validity, legally binding effect or enforceability of any provision that permits holders to
collect any portion of stated principal amount upon acceleration of the Debt Securities to the extent determined to constitute unearned interest.

2. When the Warrant Agreement to be entered into in connection with the issuance of any Warrants has been duly
authorized, executed and delivered by the Warrant Agent and the Company; the specific terms of the Warrants have been duly authorized and established in accordance with the Warrant Agreement; and such Warrants have been duly authorized, executed,
issued and delivered in accordance with the Warrant Agreement and the applicable underwriting or other agreement against payment therefor, such Warrants will constitute valid and binding obligations of the Company, enforceable in accordance with
their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors' rights generally, concepts of reasonableness and equitable principles of general applicability, and may be subject to possible judicial or
regulatory actions giving effect to governmental actions or foreign laws affecting creditors' rights.

3. When the Purchase Contract Agreement to be entered into in connection with the issuance of any Purchase
Contracts has been duly authorized, executed and delivered by the Purchase Contract Agent and the Company; the specific terms of the Purchase Contracts have been duly authorized and established in accordance with the Purchase Contract Agreement; and
such Purchase Contracts have been duly authorized, executed, issued and delivered in accordance with the Purchase Contract Agreement and the applicable underwriting or other agreement against payment therefor, such Purchase Contracts will constitute
valid and binding obligations of the Company, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors' rights generally, concepts of reasonableness and equitable principles
of general applicability, and may be subject to possible judicial or regulatory actions giving effect to governmental actions or foreign laws affecting creditors' rights.

4. When the Unit Agreement to be entered into in connection with the issuance of any Units has been duly
authorized, executed and delivered by the Unit Agent and the Company; the specific terms of the Units have been duly authorized and established in accordance with the Unit Agreement; and such Units have been duly authorized, executed, issued and
delivered in accordance with the Unit

September 2, 2025 2

------

---

| | |
|:---|:---|
| ![LOGO](g949871g63o40.jpg) | Royalty Pharma plc |

---

Agreement and the applicable underwriting or other agreement against payment therefor, such Units will constitute valid and binding obligations of the Company, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors' rights generally, concepts of reasonableness and equitable principles of general applicability, and may be subject to possible judicial or regulatory actions giving effect to governmental actions or foreign laws affecting creditors' rights.

In connection with the opinions expressed above, we have assumed that, at or prior to the time of the delivery of any such security, (i) the Board of Directors of the Company and the Board of Directors or other governing body of the Guarantors, as the case may be shall have duly established the terms of such security and duly authorized the issuance and sale of such security and such authorization shall not have been modified or rescinded; (ii) each of the Company and the Guarantors is, and shall remain, validly existing as a corporation in good standing under the laws of its respective jurisdiction of incorporation; (iii) the Registration Statement shall have become effective and such effectiveness shall not have been terminated or rescinded; and (iv) the Indentures, the Debt Securities, the Warrant Agreement, the Purchase Contract Agreement, the Unit Agreement and the Guarantees are each valid, binding and enforceable agreements of each party thereto (other than as expressly covered above in respect of the Company and each Guarantor); and (v) there shall not have occurred any change in law affecting the validity or enforceability of such security. We have also assumed that (i) the terms of any security whose terms are established subsequent to the date hereof and the issuance, execution, delivery and performance by the Company or any Guarantor of any such security (a) other than with respect to Royalty Pharma Manager, LLC, are within their corporate powers, (b) other than with respect to Royalty Pharma Manager, LLC, do not contravene, or constitute a default under, the certificate of incorporation or bylaws or other constitutive documents of the Company or any Guarantor, (c) require no action by or in respect of, or filing with, any governmental body, agency or official and (d) do not contravene, or constitute a default under, any provision of applicable law or public policy or regulation or any judgment, injunction, order or decree or any agreement or other instrument binding upon the Company or any Guarantor and (ii) any Warrant Agreement, Purchase Contract Agreement and Unit Agreement will be governed by the laws of the State of New York.

We are members of the Bar of the State of New York and the foregoing opinion is limited to the laws of the State of New York and the Limited Liability Company Act of the State of Delaware.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement referred to above and further consent to the reference to our name under the caption "Legal Matters" in the prospectus, which is a part of the Registration Statement. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act.

Very truly yours,

/s/ Davis Polk & Wardwell LLP

September 2, 2025 3

------

---

| | |
|:---|:---|
| ![LOGO](g949871g63o40.jpg) | Royalty Pharma plc |

---

Schedule 1

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Royalty Pharma Holdings Ltd, a private limited company organized under the laws of England and Wales

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Royalty Pharma Manager, LLC, a Delaware limited liability company

September 2, 2025 4

## Exhibit 23.1

**Exhibit 23.1** 

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption "Experts" in the Registration Statement (Form S-3) and related Prospectus of Royalty Pharma plc for the registration of Class A ordinary shares, preference shares, debt securities, warrants, purchase contracts and units and to the incorporation by reference therein of our reports dated February 12, 2025, with respect to the consolidated financial statements of Royalty Pharma plc, and the effectiveness of internal control over financial reporting of Royalty Pharma plc included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

New York, NY

September 2, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-3**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Royalty Pharma plc**  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Security Type**  | **Security Class Title**  | **Fee Calculation or Carry Forward Rule**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | 1 | Equity | Class A Ordinary Shares, nominal value $0.0001 per share | 457(r) |  | 0.0001531 |  |
| Fees to be Paid | 2 | Equity | Preference Shares | 457(r) |  | 0.0001531 |  |
| Fees to be Paid | 3 | Debt | Debt Securities | 457(r) |  | 0.0001531 |  |
| Fees to be Paid | 4 | Other | Warrants | 457(r) |  | 0.0001531 |  |
| Fees to be Paid | 5 | Other | Purchase Contracts | 457(r) |  | 0.0001531 |  |
| Fees to be Paid | 6 | Other | Units | 457(r) |  | 0.0001531 |  |
| Fees to be Paid | 7 | Other | Guarantees | 457(r) |  | 0.0001531 |  |
| Fees Previously Paid |  |  |  |  |  |  |  |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |
|  |  |  | Total Offering Amounts: | Total Offering Amounts: | $0.00  |  | $0.00  |
|  |  |  | Total Fees Previously Paid:  | Total Fees Previously Paid:  |  |  | $0.00  |
|  |  |  | Total Fee Offsets:  | Total Fee Offsets:  |  |  | $0.00  |
|  |  |  | Net Fee Due:  | Net Fee Due:  |  |  | $0.00  |

---

 **Offering Note** <br>

<sup>1</sup> An indeterminate aggregate initial offering price and number or amount of the securities of each identified class is being registered as may from time to time be issued at indeterminate prices pursuant to this Registration Statement. In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, Royalty Pharma plc is deferring payment of all of the registration fee. Registration fees will be paid subsequently on a ''pay as you go'' basis. Royalty Pharma plc will calculate the registration fee applicable to an offer of securities pursuant to this Registration Statement based on the fee payment rate in effect on the date of such fee payment.

<sup>2</sup> An indeterminate aggregate initial offering price and number or amount of the securities of each identified class is being registered as may from time to time be issued at indeterminate prices pursuant to this Registration Statement. In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, Royalty Pharma plc is deferring payment of all of the registration fee. Registration fees will be paid subsequently on a ''pay as you go'' basis. Royalty Pharma plc will calculate the registration fee applicable to an offer of securities pursuant to this Registration Statement based on the fee payment rate in effect on the date of such fee payment.

<sup>3</sup> An indeterminate aggregate initial offering price and number or amount of the securities of each identified class is being registered as may from time to time be issued at indeterminate prices pursuant to this Registration Statement. In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, Royalty Pharma plc is deferring payment of all of the registration fee. Registration fees will be paid subsequently on a ''pay as you go'' basis. Royalty Pharma plc will calculate the registration fee applicable to an offer of securities pursuant to this Registration Statement based on the fee payment rate in effect on the date of such fee payment.

<sup>4</sup> An indeterminate aggregate initial offering price and number or amount of the securities of each identified class is being registered as may from time to time be issued at indeterminate prices pursuant to this Registration Statement. In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, Royalty Pharma plc is deferring payment of all of the registration fee. Registration fees will be paid subsequently on a ''pay as you go'' basis. Royalty Pharma plc will calculate the registration fee applicable to an offer of securities pursuant to this Registration Statement based on the fee payment rate in effect on the date of such fee payment.

<sup>5</sup> An indeterminate aggregate initial offering price and number or amount of the securities of each identified class is being registered as may from time to time be issued at indeterminate prices pursuant to this Registration Statement. In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, Royalty Pharma plc is deferring payment of all of the registration fee. Registration fees will be paid subsequently on a ''pay as you go'' basis. Royalty Pharma plc will calculate the registration fee applicable to an offer of securities pursuant to this Registration Statement based on the fee payment rate in effect on the date of such fee payment.

<sup>6</sup> An indeterminate aggregate initial offering price and number or amount of the securities of each identified class is being registered as may from time to time be issued at indeterminate prices pursuant to this Registration Statement. In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, Royalty Pharma plc is deferring payment of all of the registration fee. Registration fees will be paid subsequently on a ''pay as you go'' basis. Royalty Pharma plc will calculate the registration fee applicable to an offer of securities pursuant to this Registration Statement based on the fee payment rate in effect on the date of such fee payment.

<sup>7</sup> An indeterminate aggregate initial offering price and number or amount of the securities of each identified class is being registered as may from time to time be issued at indeterminate prices pursuant to this Registration Statement. In accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended, Royalty Pharma plc is deferring payment of all of the registration fee. Registration fees will be paid subsequently on a ''pay as you go'' basis. Royalty Pharma plc will calculate the registration fee applicable to an offer of securities pursuant to this Registration Statement based on the fee payment rate in effect on the date of such fee payment.

---

| | |
|:---|:---|
| | |
| **Rules 457(b) and 0-11(a)(2)** | **Rules 457(b) and 0-11(a)(2)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Amount of Securities Previously Registered**  | **Maximum Aggregate Offering Price of Securities Previously Registered**  | **Form Type**  | **File Number**  | **Initial Effective Date**  |
| N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |

---